RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer

Gynecologic Oncology

Volumn 124, Issue 3, 2012, Pages 589-597

  Vishnu, Prakash ^a   Colon Otero, Gerardo ^a   Kennedy, Gregory T ^a   Marlow, Laura A ^a   Kennedy, William P ^a   Wu, Kevin J ^a   Santoso, Joseph T ^b   Copland, John A ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Ixabepilone; Ovarian cancer; Receptor tyrosine kinase; RhoB; Sunitinib

Indexed keywords

GUANOSINE TRIPHOSPHATASE; IXABEPILONE; PACLITAXEL DERIVATIVE; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; SHORT HAIRPIN RNA; SUNITINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EPOTHILONES; FEMALE; HUMANS; INDOLES; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PYRROLES; RHOB GTP-BINDING PROTEIN; UP-REGULATION;

EID: 84856764981     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.11.019     Document Type: Article

References (44)

1. SEER Stat Fact Sheets: Ovary. National Cancer Institute http://seer.cancer.gov/statfacts/html/urinb.html 2010 Accessed 03/31/2011
2. A.P. Heintz, F. Odicino, and P. Maisonneuve Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer Int J Gynaecol Obstet 95 Suppl. 1 Nov 2006 S161 192
3. R.A. Soslow Histologic subtypes of ovarian carcinoma: an overview Int J Gynecol Pathol 27 2 Apr 2008 161 174
4. R.C. Bast Jr., B. Hennessy, and G.B. Mills The biology of ovarian cancer: new opportunities for translation Nat Rev Cancer 9 6 Jun 2009 415 428
5. D.A. Bell Origins and molecular pathology of ovarian cancer Mod Pathol 18 Suppl. 2 Feb 2005 S19 S32
6. E. Despierre, D. Lambrechts, P. Neven, F. Amant, S. Lambrechts, and I. Vergote The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment Gynecol Oncol 117 2 May 2010 358 365
7. S. Yamamoto, H. Tsuda, and T. Kita Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma Virchows Arch 451 1 Jul 2007 27 35
8. B. Couderc, A. Pradines, and A. Rafii In vivo restoration of RhoB expression leads to ovarian tumor regression Cancer Gene Ther 15 7 Jul 2008 456 464
9. F.J. de la Torre, A. Garcia, and A. Gil-Moreno Apoptosis in epithelial ovarian tumours. Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax) Eur J Obstet Gynecol Reprod Biol 130 1 Jan 2007 121 128
10. A. Berchuck, G.J. Olt, L. Everitt, A.P. Soisson, R.C. Bast Jr., and C.M. Boyer The role of peptide growth factors in epithelial ovarian cancer Obstet Gynecol 75 2 Feb 1990 255 262
11. S.P. Wilczynski, Y.Y. Chen, W. Chen, S.B. Howell, J.E. Shively, and D.S. Alberts Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers Hum Pathol 36 3 Mar 2005 242 249
12. A. Berchuck, A. Kamel, and R. Whitaker Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer Cancer Res 50 13 1990 4087 4091
13. M.B. Dabrow, M.R. Francesco, F.X. McBrearty, and S. Caradonna The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium Gynecol Oncol 71 1 Oct 1998 29 37
14. M. Fraser, B. Leung, A. Jahani-Asl, X. Yan, W.E. Thompson, and B.K. Tsang Chemoresistance in human ovarian cancer: the role of apoptotic regulators Reprod Biol Endocrinol 1 Oct 7 2003 66
15. S.C. Rubin, C.L. Finstad, G.Y. Wong, L. Almadrones, M. Plante, and K.O. Lloyd Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis Am J Obstet Gynecol 168 1 Pt 1 Jan 1993 162 169
16. L.A. Marlow, L.A. Reynolds, and A.S. Cleland Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth Cancer Res 69 4 2009 1536 1544
17. G.C. Prendergast Actin' up: RhoB in cancer and apoptosis Nat Rev Cancer 1 2 Nov 2001 162 168
18. K. Jiang, J. Sun, J. Cheng, J.Y. Djeu, S. Wei, and S. Sebti Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis Mol Cell Biol 24 12 Jun 2004 5565 5576
19. NCCN Clinical Practice Guidelines in Oncology / Ovarian Cancer v 2.2011 http://www.nccn.org/professionals/physician-gls/pdf/ovarian.pdf 2011 Accessed 05/03/2010
20. J.A. Ledermann, and R.S. Kristeleit Optimal treatment for relapsing ovarian cancer Ann Oncol 21 Suppl. 7 Oct 2010 vii218 vii222
21. K. De Geest, J.A. Blessing, and R.T. Morris Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study J Clin Oncol 28 1 2010 149 153
22. C. Dumontet, M.A. Jordan, and F.F. Lee Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies Mol Cancer Ther 8 1 Jan 2009 17 25
23. F.Y. Lee, R. Borzilleri, and C.R. Fairchild BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy Clin Cancer Res 7 5 May 2001 1429 1437
24. E.S. Thomas, H.L. Gomez, and R.K. Li Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 33 2007 5210 5217
25. M.N. Bijman, G.P. van Nieuw Amerongen, N. Laurens, V.W. van Hinsbergh, and E. Boven Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton Mol Cancer Ther 5 9 Sep 2006 2348 2357
26. D. Jelovac, and D.K. Armstrong Recent progress in the diagnosis and treatment of ovarian cancer CA Cancer J Clin 61 3 May-Jun 2011 183 203
27. Calcusyn windows software for dose effect analysis [computer program] 1996 Biosoft Cambridge, MA
28. T.-C. Chou, and P. Talalay Analysis of combined drug effects: a new look at a very old problem Trends Pharmacol Sci 4 1983 450 454
29. R.B. Montgomery, J. Guzman, D.M. O'Rourke, and W.L. Stahl Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression J Biol Chem 275 23 2000 17358 17363
30. J.W. Xu, Q.Q. Li, L.L. Tao, Y.Y. Cheng, J. Yu, Q. Chen, X.P. Liu, and Z.D. Xu Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells Int J Oncol 39 6 Dec 2011 1501 1509
31. J.E. Busby, S.J. Kim, and S. Yazici Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells Prostate 66 16 2006 1788 1798
32. Targeted cancer therapies http://www.cancer.gov/cancertopics/factsheet/ Therapy/targeted 2011 Accessed 8/29/2011
33. J. Tabernero The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents Mol Cancer Res 5 3 Mar 2007 203 220
34. M.F. Press, and H.J. Lenz EGFR, HER2 and VEGF pathways: validated targets for cancer treatment Drugs 67 14 2007 2045 2075
35. K.H. Tkaczuk Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer Clin Ther 31 Pt 2 2009 2273 2289
36. C.L. Dai, Y.J. Liang, and Y.S. Wang Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2 Cancer Lett 279 1 2009 74 83
37. S. Shukla, R.W. Robey, S.E. Bates, and S.V. Ambudkar Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2 Drug Metab Dispos 37 2 Feb 2009 359 365
38. H.S. Kim, J.M. Oh, D.H. Jin, K.H. Yang, and E.Y. Moon Paclitaxel induces vascular endothelial growth factor expression through reactive oxygen species production Pharmacology 81 4 2008 317 324
39. D. Matei, R.E. Emerson, and Y.C. Lai Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer Oncogene 25 14 2006 2060 2069
40. F. Yang, V. Jove, H. Xin, M. Hedvat, T.E. Van Meter, and H. Yu Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways Mol Cancer Res 8 1 Jan 2010 35 45
41. M.S. Fenton, K.M. Marion, A.K. Salem, R. Hogen, F. Naeim, and J.M. Hershman Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer Thyroid 20 9 Sep 2010 965 974
42. E. Vasilaki, E. Papadimitriou, V. Tajadura, A.J. Ridley, C. Stournaras, and D. Kardassis Transcriptional regulation of the small GTPase RhoB gene by TGF{beta}-induced signaling pathways FASEB J 24 3 Mar 2010 891 905
43. D.O. Bauerschlag, C. Schem, and S. Tiwari Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice Anticancer Res 30 9 Sep 2010 3355 3360
44. J.J. Biagi, A.M. Oza, and H.I. Chalchal A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study Ann Oncol 22 2 Feb 2011 335 340